Cyclophosphamide, Adriamycin and Cisplatin (CAP) versus Cyclophosphamide, Adriamycin and Vincristin (CAV) in the treatment of advanced ovarian cancer: A randomized study
نویسندگان
چکیده
منابع مشابه
SALVAGE CHEMO THERAPY WITH CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN (CAP) IN ADVANCED BREAST CANCER
Twenty-one patients with advanced breast cancer (7 premenopausal and 14 postmenopausal women) were treated with a combination of cyclophosphamide, doxorubicin, and cisplatin (CAP). The median age of the patients was 43 years (range 36-61). This therapy was repeated every 3 weeks. Nine patients (group 1) received CAP as primary therapy for metastatic breast cancer, and twelve patients (group...
متن کاملsalvage chemo therapy with cyclophosphamide, doxorubicin, and cisplatin (cap) in advanced breast cancer
twenty-one patients with advanced breast cancer (7 premenopausal and 14 postmenopausal women) were treated with a combination of cyclophosphamide, doxorubicin, and cisplatin (cap). the median age of the patients was 43 years (range 36-61). this therapy was repeated every 3 weeks. nine patients (group 1) received cap as primary therapy for metastatic breast cancer, and twelve patients (group 2) ...
متن کاملComparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
PURPOSE Neoadjuvant chemotherapy is the standard treatment for patients with locally advanced breast cancer and is increasingly considered for patients with operable disease. Recently, as many clinical trials have demonstrated favorable outcomes of anthracycline-taxane based regimen, this approach has been widely used in the neoadjuvant setting. METHODS We compared women who received adriamyc...
متن کاملA 1 Adriamycin - Cyclophosphamide ( AC ) followed by Paclitaxel - Cisplatin ( PC ) . A highly active neoadjuvant regimen in locally advanced breast cancer
A1 Adriamycin-Cyclophosphamide (AC) followed by Paclitaxel-Cisplatin (PC). A highly active neoadjuvant regimen in locally advanced breast cancer Daniel Mendoza-Posada, Teresa Vela-Chavez, Enrique Bargallo-Rocha, Nestor Villafañe, Carlos Gamboa-Vignole and Claudia Arce Department of Medical Oncology, INCAN México Department of Pathology, INCAN México Department of Breast Tumors, INCAN México Dep...
متن کاملAdriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
Combination of cyclophosphamide and adriamycin, encompassing a wide range of dosages, were administered on five different schedules to C57BL/6J X DBA/2J F1 female mice inoculated i.p. with L1210 ascites tumor cells. Among the resulting 85 treatment groups, the mean postinoculation survival of mice that died with tumor was 11.4 to 51.3 days; this represented increases of 62 to 628% over the surv...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 1992
ISSN: 0923-7534
DOI: 10.1093/oxfordjournals.annonc.a058063